Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [41] Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs)
    Seruga, B.
    Sterling, L.
    Wang, L.
    Tannock, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Emerging drugs for managing kidney disease in patients with diabetes
    Thomas, Merlin C.
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (01) : 55 - 70
  • [43] Autophagy targeted in kidney cancer
    Bethan Hughes
    Nature Reviews Drug Discovery, 2008, 7 : 731 - 731
  • [44] Autophagy targeted in kidney cancer
    Hughes, Bethan
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) : 731 - 731
  • [45] Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
    Shuch, Brian
    Riggs, Stephen B.
    LaRochelle, Jeff C.
    Kabbinavar, Fairooz F.
    Avakian, Raffi
    Pantuck, Allan J.
    Patard, Jean-Jacques
    Belldegrun, Arie S.
    BJU INTERNATIONAL, 2008, 102 (06) : 692 - 696
  • [46] Kidney Toxicities Associated With Novel Cancer Therapies
    Lefebvre, Joannie
    Glezerman, Ilya G.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2017, 24 (04) : 233 - 240
  • [47] Nuances to precision dosing strategies of targeted cancer medicines
    Hopkins, Ashley M.
    Menz, Bradley D.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    Gurney, Howard
    McKinnon, Ross A.
    Rowland, Andrew
    Sorich, Michael J.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (04):
  • [48] Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma
    Ryan, Christopher W.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (01) : 43 - 55
  • [49] Mitochondria-targeted drugs for diabetic kidney disease
    Mima, Akira
    HELIYON, 2022, 8 (02)
  • [50] Managing dermatologic changes of targeted cancer therapy
    Zarrabi, Kevin
    Gemmill, Julie Anne L.
    Safaee, Maryam
    Baer, Lea
    JOURNAL OF FAMILY PRACTICE, 2019, 68 (06): : 334 - 340
12345